DXNVX Signs Research Contract for Development of Customized Immunotherapy Biomarkers

[Asia Economy Reporter Jang Hyowon] Dx&Vx announced on the 30th that it has signed a contract for a basic medical research precision medicine genomic analysis service research outsourcing (CRO) worth 3 billion KRW annually with COREE for the purpose of building big data for the health industry and new drug development.

This research project, which started in 2022, aims to create big data from more than 10,000 immune cell profiling results over three years.

COREE, which is focusing on investment in the health industry, is conducting maternal and child health clinical research with China’s Xiehe Hospital and clinical research on diabetes, obesity, and metabolic chronic diseases with Italy’s Gemelli Hospital.

This genomic analysis service investment with Dx&Vx is a research clinical investment to analyze biological data related to infectious diseases to enable practical use in future diagnostics and personalized immune therapy development. Clinical research on maternal and child health, chronic diseases, and immune diseases is expected to bring socially positive ripple effects such as reducing medical expenses and improving research cost efficiency.

Park Sangtae, CEO of Dx&Vx, said, “As part of the Genomic CRO business, we conducted genomic analysis of 3,156 whole genomes and immune cell-related genomes profiled by immune cells, divided into four cohort groups over the past year.” He added, “This database can also be used for biomarker development of personalized immune therapies in the future based on the clinical results of cancer vaccines from our overseas affiliate Oxford Vacmedix.”

Park also added, “Through this second phase of research, we plan to supplement data such as Cell free DNA-seq and RNA-seq to be utilized for the development of Multi-Omics Biomarkers.”

Currently, Dx&Vx operates the Molecular Genetics Research Institute and the Microbiome Research Institute. Based on the multi-omics research of these two institutes, they are building and expanding various pipelines based on diagnostics and microbiomes, including Omic-Check S-Health, Omic-Check S-Beauty, and the development of dual diagnostic kits for Norovirus and Rotavirus for export to China.